Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of PDS Biotechnology Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001472091.
Disclosed value leader
VANGUARD CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- PDSB on Nasdaq
- Parsed ownership sources
-
13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001472091
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PDS Biotechnology Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
VANGUARD CAPITAL MANAGEME...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
Lead comparable stake: 3.4%
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 3.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
3.4%
Focus Partners Wealth
1.3%
Quantinno Capital Management LP
1.3%
BlackRock, Inc.
1.2%
GEODE CAPITAL MANAGEMENT, LLC
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.4%
|
$1,497,097
1,699,315 shares
|
— | 30 Jun 2026 |
| Focus Partners Wealth |
13F
Company
|
1.3%
|
$565,822
642,177 shares
|
— | 30 Jun 2026 |
| Quantinno Capital Management LP |
13F
Company
|
1.3%
|
$565,822
642,177 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
1.2%
|
$535,391
607,639 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.2%
|
$517,410
587,139 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.72%
|
$314,644
357,144 shares
|
— | 30 Jun 2026 |
| Militia Capital Management LLC |
13F
Company
|
0.67%
|
$292,349
331,800 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.65%
|
$285,301
323,801 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to PDS Biotechnology Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
DeLyle W. Bloomquist
Net 12M change
$0
Latest report
12 Jan 2026
Recent insider transactions for PDS Biotechnology Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Frank Bedu-Addo | PDSB | Employee Stock Option (Right to Buy) | Award | 548,782 | 548,782 | 12 Jan 2026 | Direct | |||
| Gregory Conn | PDSB | Employee Stock Option (Right to Buy) | Award | 150,000 | 150,000 | 12 Jan 2026 | Direct | |||
| Kirk V Shepard | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Lars Boesgaard | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Spencer D. Brown | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Stephan Toutain | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Gregory Gene Freitag | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Ilian Iliev | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Kamil Ali-Jackson | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Otis W. Brawley | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Stephen C. Glover | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.